Research programme: interleukin-17A inhibitors - Nuevolution
Alternative Names: Cytokine X; IL-17A inhibitorsLatest Information Update: 28 Sep 2022
At a glance
- Originator Nuevolution
- Class Anti-inflammatories; Antipsoriatics; Small molecules
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Inflammation in Denmark (PO, Tablet)
- 28 Sep 2022 No recent reports of development identified for research development in Inflammation in Denmark (Topical)
- 30 Jul 2019 Nuevolution has been acquired by Amgen